Quick Answer
Can-Fite BioPharma Ltd. reported Earnings Per Share Diluted of $5.97 (loss) per share for the year ending 2025.
- Can-Fite BioPharma Ltd. showed an increase of +45.0% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Can-Fite BioPharma Ltd.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 6 years of available data (2020 to 2025), Can-Fite BioPharma Ltd.'s Earnings Per Share Diluted has declined by 14,825.0%.
- Historical annual values: Fiscal year 2025: $5.97 (loss) per share | Fiscal year 2024: $10.86 (loss) per share | Fiscal year 2023: $17.92 (loss) per share | Fiscal year 2022: $0.01 (loss) per share | Fiscal year 2021: $0.03 (loss) per share | Fiscal year 2020: $0.04 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: